Low-Dose CBD Did Not Help Active Crohn's Disease in This Small Trial | Research

The takeaway

In a randomized trial of 20 patients with moderately active Crohn's disease, CBD at 10 mg twice daily was safe but produced no clinical benefit over placebo.

Read this if you have Crohn's disease and are considering CBD oil as a treatment.

CBD 10 mg twice daily showed no benefit over placebo in 20 Crohn's patients

What the researchers found

This randomized, placebo-controlled trial tested oral CBD (10 mg twice daily) in 20 patients with moderately active Crohn's disease who had not responded to standard treatments.

After 8 weeks of treatment, both the CBD and placebo groups showed similar improvements in disease activity (CDAI decreased from 337 to 220 in CBD group vs. 308 to 216 in placebo), with no statistically significant difference between them.

CBD was safe: no side effects were observed, and liver function, kidney function, hemoglobin, and albumin all remained unchanged.

The authors acknowledged several possible explanations for the null result: CBD may genuinely not help Crohn's disease, or the dose may have been too low, the sample too small, or the lack of synergism with other cannabinoids (like THC) may have limited effectiveness.

Why it matters

This is one of the few randomized controlled trials testing CBD specifically (without THC) for inflammatory bowel disease. The null result at low dose is important because it tempers the enthusiasm generated by preclinical studies showing CBD's anti-inflammatory effects.

The numbers in context

20 patients (19 completed). CDAI before: 337 vs. 308 (CBD vs. placebo). CDAI after 8 weeks: 220 vs. 216 (p = NS). CBD dose: 10 mg twice daily. No side effects.

How the study worked

Randomized, placebo-controlled trial of 20 patients aged 18-75 with CDAI >200 (moderately active Crohn's). Oral CBD 10 mg or placebo twice daily for 8 weeks plus 2 weeks follow-up. Patients had failed standard treatments (steroids, thiopurines, TNF antagonists). ClinicalTrials.gov: NCT01037322.

What this study cannot tell us

Very small sample (20 patients). Very low CBD dose (10 mg BID, far below doses used in epilepsy trials of 10-20 mg/kg/day). No THC component, which may be necessary for entourage effects. Short treatment duration.

How to read the evidence

Randomized controlled trial with adequate methodology. Moderate despite small size because the RCT design provides relatively strong evidence for the null finding.

When this study was published

Published in 2017.

The bigger picture

The discrepancy between strong preclinical anti-inflammatory data and this negative clinical trial highlights the challenge of translating laboratory findings to patient outcomes. The dose-response question is critical: 10 mg twice daily may be far below the doses used in successful animal studies.

Questions still open

Would higher CBD doses (100-300 mg/day) show efficacy for Crohn's? Would CBD combined with THC be more effective? Is the placebo response in IBD trials too strong for small studies to overcome?

Common questions

Does CBD help Crohn's disease?

This trial found CBD at 10 mg twice daily was no more effective than placebo for moderately active Crohn's. However, the dose was very low compared to doses used in other conditions, so higher doses might produce different results.

Is CBD safe for Crohn's patients?

Yes. No side effects were observed and all safety laboratory tests remained normal throughout the 8-week trial. CBD at this dose appears safe even if it was not effective.

Read the original research

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.

Digestive diseases and sciences, 62(6), 1615-1620

View on PubMed ↗Publisher’s paper ↗

Citation

Naftali, Timna; Mechulam, Refael; Marii, Amir; Gabay, Gila; Stein, Asaf; Bronshtain, Miriam; Laish, Ido; Benjaminov, Fabiana; Konikoff, Fred M. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.. Digestive diseases and sciences, 62(6), 1615-1620. https://doi.org/10.1007/s10620-017-4540-z